Successfully treating type 2 diabetes may involve focusing on brain neurons, rather than simply concentrating on obesity or insulin resistance, according to a study published today in the Journal of ...

A new research paper shows that, in some ways, U.S. prescription drug spending is not necessarily all that high.

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

A new report from the Access to Medicine Foundation has revealed a deepening crisis in access to diabetes care for children ...

Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...

Global cases of Type 1 diabetes - an autoimmune disease common among Children and Young People (CYP) - is expected to reach 2.2 million by 2040, this according to a report by Access to Medicine ...

Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...

Novo Nordisk and Septerna enter $2.2 billion deal to develop oral small-molecule therapies targeting obesity, diabetes, and ...

COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral ...